Showing 5401-5410 of 7686 results for "".
- Smoking, BMI, and Age Affect Biologic Outcomes in Psoriasis: Analysishttps://practicaldermatology.com/news/smoking-bmi-and-age-affect-biologic-outcomes-psoriasis-analysis/2467138/A new systematic review and meta-analysis revealed a number of factors that can make patients with psoriasis have a poorer response to biologics. Researchers for the study used data from PubMed, Embase, and Web of Science reporting treatment outcomes using Psoriasis Area and Severity Ind
- PD-1 Gene Variants Linked to Melanoma Riskhttps://practicaldermatology.com/news/pd-1-gene-variants-linked-melanoma-risk/2467088/A recent study has highlighted significant associations between specific single nucleotide variants (SNVs) in the PD-1 and PD-L1 genes and the risk of metastatic melanoma (MM). Researchers conducted the study at IRCCS Ospedale Policlinico San Martino in Genova, Italy, and included 125 patients wi
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- Study: Advanced AI Enhances Melanoma Detectionhttps://practicaldermatology.com/news/study-advanced-ai-enhances-melanoma-detection/2467071/A new study suggests a novel deep-learning model based on diagnostic data may help harness the power of neural networks and artificial intelligence (AI) to more accurately diagnose melanoma.
- Survey: 43% With Acne Worry They'll Never Have Clear Skinhttps://practicaldermatology.com/news/survey-43-acne-worry-theyll-never-have-clear-skin/2467063/Ninety percent of acne sufferers experience daily insecurities related to their acne, and 43% worry they will never have clear skin, according to a new survey conducted by Cutera, Inc. June is Acne Awareness Month, and Cutera said in a press release that the findings of the survey “highli
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- Ruxolitinib cream 1.5% Demonstrates Tolerability, Safety Over 52 Weeks in Childrenhttps://practicaldermatology.com/news/ruxolitinib-cream-15-demonstrates-tolerability-safety-over-52-weeks-children/2467044/Ruxolitinib cream 1.5% demonstrated consistently good tolerability and safety over 52 weeks in children 2 to 11 years old with extensive moderate-to-severe atopic dermatitis (AD) in a study presented this month at the Revolutionizing Atopic Dermatitis (RAD) Conference in Chicago, Illinois.
- Moderate-to-Severe AA Linked to AD Comorbidityhttps://practicaldermatology.com/news/moderate-severe-aa-linked-ad-comorbidity/2467042/Patients with moderate-to-severe alopecia areata (AA) had higher prevalence and incidence of atopic dermatitis (AD) comorbidity and higher prevalence of moderate-to-severe AD than those with mild AA in a study presented this month at the Revolutionizing Alopecia, Vitligo, and Eczema (RAVE) Confer
- Suntegrity Recalls Multiple Lots of Sunscreen Foundationhttps://practicaldermatology.com/news/suntegrity-recalls-multiple-lots-sunscreen-foundation/2467041/Suntegrity Skincare has announced that it is recalling nine lots of Suntegrity Impeccable Skin Sunscreen Foundation (Multiple Shades) due to the discovery of a higher-than-acceptable microbiological mold count (Aspergillus sydowii), according to an FDA alert. According to the man
- Adtralza Pre-Filled Pen Now Available for Canadian Atopic Dermatitis Patientshttps://practicaldermatology.com/news/adtralza-pre-filled-pen-now-available-canadian-atopic-dermatitis-patients/2467019/A new Adtralza® (tralokinumab injection) pre-filled pen has been made available for the first time in Canada for the treatment of moderate-to-severe atopic dermatitis (AD), according to a press announcement from LEO Pharma Inc. The single-use 2 mL pre-filled pen "simplifies the